ArticlePatient preference and adherence2025
Normoglycemia and Weight Reduction: Perspectives of People with Type 2 Diabetes in Australia.
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differences in Perspectives of Weight Management Among People in the US and Canada with Type 2 Diabetes by Body Mass Index.Patient preference and adherence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: As more treatments become available to normalize glycated hemoglobin (HbA1c) levels and reduce weight, it is important to understand the meaningfulness of achieving target HbA1c levels and weight reduction from the perspective of people with type 2 diabetes. Patients and Methods: This is a cross-sectional survey of 300 Australians with type 2 diabetes. Results: Achieving target HbA1c levels was meaningful to 90.0% (n=198) and moderately/very/extremely important to 94.5% (n=208) of the 220 participants with HbA1c >6.0%. Over half of the participants were dissatisfied with their current weight (n=158, 52.7%) and underreported their body mass index category (n=160, 53.3%). For 59.0% (n=177), a mean (±standard deviation) of 17.2 (±20.6) kg of weight loss was meaningful. Of these participants, 10.7%, 30.5%, 21.5%, and 37.3% viewed 5%, 5-10%, 10%-15%, and >15% of weight reduction as meaningful, respectively. Conclusion: According to this survey, achieving target HbA1c levels is both meaningful and important to most people with type 2 diabetes. Achieving weight reduction is also seen as important despite frequent underrating of body mass index. Therapies targeting both target HbA1c levels and weight reduction may be of interest to people with type 2 diabetes in Australia, and this could impact medication adherence and health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.